非酒精性脂肪性肝病患者血清SDC4变化及其临床意义探讨

doi:10.3969/j.issn.1672-5069.2021.01.012

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (1): 43-46.doi: 10.3969/j.issn.1672-5069.2021.01.012

非酒精性脂肪性肝病患者血清SDC4变化及其临床意义探讨

夏淑晶, 张莉莉, 张秀梅, 赵根宝, 周松伟, 罗欲承, 陈红芹, 王子华, 成凤干, 范建高

225700 江苏省兴化市人民医院消化内科(夏淑晶,张莉莉,陈红芹,王子华,成凤干);
病理科(张秀梅);
超声科(赵根宝);
检验科(周松伟,罗欲承);
上海交通大学医学院附属新华医院消化内科(范建高)

出版日期:2021-01-10 发布日期:2021-01-19
通讯作者: 夏淑晶,女,41岁,医学博士,副主任医师。E-mail:xiashujing0611@163.com
通讯作者:范建高,E-mail:13818868519@163.com
作者简介:夏淑晶,女,41岁,医学博士,副主任医师。E-mail:xiashujing0611@163.com
基金资助:
中国肝炎防治基金会天晴肝病基金资助项目(编号:TQGB20190119)

Diagnosticvalue of serum syndecan-4 in patients with nonalcoholic fatty liver disease

Xia Shujing, Zhang Lili, Zhang Xiumei, et al

Department of Gastroenterology, Xinghua People’s Hospital, Xinghua 225700, Jiangsu Province, China

Online:2021-01-10 Published:2021-01-19

摘要/Abstract

摘要： 目的探讨血清多配体蛋白聚糖-4(SDC4)水平诊断非酒精性脂肪性肝病(NAFLD)患者的效能。方法 2019年6月～12月无过量饮酒史的健康体检成人,使用超声检查诊断NAFLD,采用ELISA法检测血清SDC4水平,采用多元Logistic回归分析影响脂肪肝发生的危险因素,应用受试者工作特征曲线(ROC)下面积(AUC)分析诊断效能。结果在209例体检成人中,发现NAFLD患者102例,健康人107例;NAFLD组血清SDC4水平显著高于健康人(11.7±4.2 ng/mL对5.3±2.5 ng/mL,P < 0.05),血清SDC4水平随着NAFLD患者脂肪肝程度的加重呈显著上升趋势;Logistic回归分析发现,血清SDC4增高与NAFLD发生独立相关;以血清SDC4水平为8.45 ng/mL为诊断NAFLD的截断点,AUC为0.917,其敏感度为84.3％,特异度为87.9％。结论血清SDC4增高可能与肥胖、代谢紊乱和NAFLD的发生密切相关,检测血清SDC4水平可能有助于无创诊断NAFLD。

关键词: 非酒精性脂肪性肝病, 多配体蛋白聚糖-4, 诊断

Abstract: Objective To investigate the diagnostic value of serum syndecan-4 (SDC4) in patients with nonalcoholic fatty liver disease (NAFLD). Methods The individuals having no history of excessive alcohol consumption were selected between June to December 2019, and all underwent ultrasonography. Serum SDC4 level was detected by enzyme-linked immunosorbent assay. The univariate and multivariate analysis and the receiver operating characteristic curve (ROC) were applied to analyze the diagnostic value of serum SDC4 level for NAFLD. Results A total of 209 adults were included in this study, including 102 patients with NAFLD and 107 healthy persons after US check-up; serum SDC4 level in patients with NAFLD was significantly higher than that in the control group (11.7±4.2 ng / mL vs. 5.3±2.5 ng / mL, P < 0.05), and serum SDC4 levels increased significantly as the severity of fatty liver became severe in patients with NAFLD; the Logistic regression analysis found that the increased serum SDC4 level was independently related to NAFLD occurrence; when serum SDC4 level equal to or greater than 8.45 ng/mL as the cut-off-value, the area under ROC was 0.917, with the sensitivity of 84.3% and the specificity of 87.9%. Conclusion The increased serum SDC4 levels could be closely related to obesity, metabolic disorders and the incidence of NAFLD, and the detection of serum SDC4 levels might be helpful for non-invasive diagnosis of NAFLD.

Key words: Non-alcoholic fatty liver diseases, Polyligand proteoglycan-4, Diagnosis

夏淑晶, 张莉莉, 张秀梅, 赵根宝, 周松伟, 罗欲承, 陈红芹, 王子华, 成凤干, 范建高. 非酒精性脂肪性肝病患者血清SDC4变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 43-46.

Xia Shujing, Zhang Lili, Zhang Xiumei, et al. Diagnosticvalue of serum syndecan-4 in patients with nonalcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2021, 24(1): 43-46.

参考文献

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2):30-39.
[2] 邵幼林, 范建高.非酒精性脂肪性肝病的流行现状与危害.中华肝脏病杂志,2019, 27(1):10-13.
[3] 涂宏飞, 费素娟. 肠道微生态与非酒精性脂肪性肝病. 肝脏, 2018(4):347-349.
[4] 刘玉, 成飞, 罗玉璇,等.基因表达谱分析非酒精性脂肪肝中细胞色素P450的作用.中华肝脏病杂志,2017,25(4):285-290.
[5] Binch ALA, Shapiro IM, Risbud MV.Syndecan-4 in intervertebral disc and cartilage: Saint or synner? Matrix Biol,2016, 52-54.
[6] Jeyarajah MJ, Jaju Bhattad G, Kops BF,et al.Syndecan-4 regulates extravillous trophoblast migration by coordinating protein kinase C activation. Sci Rep,2019, 9(1):10175-10189.
[7] Das S, Monteforte AJ, Singh G, et al.Syndecan-4 enhances therapeutic angiogenesis after hind limb ischemia in mice with type 2 diabetes. Adv Healthc Mater,2016, 5(9):1008-1013.
[8] Gopal S, Multhaupt HAB, Pocock R, et al. Cell-extracellular matrix and cell-cell adhesion are linked by syndecan-4. Matrix Biol,2017, 60-61.
[9] 范建高.中国非酒精性脂肪性肝病诊疗指南(2010年修订版).中国医学前沿杂志(电子版),2012, 4(7):4-10.
[10] 林栋, 管庆波.2型糖尿病男性患者血清睾酮水平低下对非酒精性脂肪肝的影响.山东大学学报:医学版,2016, 54 (7):33-37.
[11] Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact.J Hepatol,2018, 68(2):268-279.
[12] Papatheodoridi M, Cholongitas E. Diagnosis of non-alcoholic fatty liver disease (NAFLD): Current concepts. Curr Pharmaceut Desig,2018, 24(38):4574-4586.
[13] Frhling M, Tepasse P, Intemann J, et al.Syndecan-4 modulates epithelial gut barrier function and epithelial regeneration in experimental colitis.Inflamma Bowel Dis,2018, 24(12):2579-2589.
a) Wu H, Zhou Q, Xie J, et al. Syndecan-4 shedding is involved in the oxidative stress and inflammatory responses in left atrial tissue with valvular atrial fibrillation. Int J Clin Exp Pathol,2015, 8(6):6387-6396.
b) Teixeira FCOB, Gtte M. Involvement of syndecan-1 and heparanase in cancer and inflammation. Adv Exp Med Biol, 2020,1221:97-135.
c) Beauvais DM, Jung O, Yang Y, et al.Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: Prevention by synstatin IGF1R inhibits tumor growth. Cancer Res,2016, 76(17):4981-4993.
d) Rose G, Crocco P, De Rango F, et al. Metabolism and successful aging: Polymorphic variation of syndecan-4 (SDC4) gene associate with longevity and lipid profile in healthy elderly Italian subjects. Mech Ageing Dev, 2015,150:27-33.
e) De Luca M, Vecchie D. Genetic deletion of syndecan-4 alters body composition, metabolic phenotypes, and the function of metabolic tissues in female mice fed a high-fat diet.Nutrients,2019, 11(11):2810-2826.
[14] 徐静远, 邵勇, 鲁晓岚,等.老年居民非酒精性脂肪性肝病的影响因素和死因分析.中华肝脏病杂志,2019, 27(3):204-209.
[15] 张力元, 盛夏, 胡平方, 等.血清高密度脂蛋白胆固醇在非酒精性脂肪性肝病风险评估中的价值.中华消化杂志,2019, 39(5):317-321.

非酒精性脂肪性肝病患者血清SDC4变化及其临床意义探讨

Diagnosticvalue of serum syndecan-4 in patients with nonalcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	荣爱梅, 张超, 吴慧丽. 西罗莫司对高脂饮食诱导的NAFLD大鼠外周血Treg/Th17细胞的影响[J]. 实用肝脏病杂志, 2021, 24(1): 10-13.
[2]	吴冬秋, 崔丽华, 熊峰, 邬政宏. 血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2021, 24(1): 23-26.
[3]	陈光榆, 王鸿, 王耀晟, 张熙, 张伟, 曾静, 沈峰, 胡颖, 范建高. 非酒精性脂肪性肝病患者血红蛋白水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 39-42.
[4]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[5]	梁小丽, 邝继孙, 刘秋莉, 符弟. 非诺贝特联合热量限制饮食治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 51-54.
[6]	赵晓春, 钟庆, 刘书宏, 梁尘格, 郭熙清, 温林. 非酒精性脂肪性肝病并发2型糖尿病患者血尿酸水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 55-58.
[7]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[8]	陈金玉, 郭晓霞, 钟晓妮. 二甲双胍联合双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝病患者疗效及血清IRS1、IRS2和GLUT4的变化[J]. 实用肝脏病杂志, 2021, 24(1): 63-66.
[9]	张昕, 郭悦, 杨军. 瞬时弹性成像测定肝脾硬度值评估乙型肝炎肝硬化患者食管静脉曲张初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 95-98.
[10]	李俊缨, 周玲, 陈金军. 非酒精性脂肪性肝病高危人群:监测与防治[J]. 实用肝脏病杂志, 2020, 23(5): 612-614.
[11]	叶俊钊, 钟碧慧. 非酒精性脂肪性肝病合并代谢并发症患者规范治疗与管理[J]. 实用肝脏病杂志, 2020, 23(5): 615-618.
[12]	方奕, 陈毅雄, 裴冬萍, 操银针. 恩替卡韦联合复方嗜酸乳杆菌治疗CHB合并NAFLD患者疗效及其对血清相关酶系的影响[J]. 实用肝脏病杂志, 2020, 23(5): 634-637.
[13]	张浩, 常建东, 陈小燕. 超声弹性成像结合血清学指标诊断慢性乙型肝炎患者肝纤维化价值评价[J]. 实用肝脏病杂志, 2020, 23(5): 642-645.
[14]	杨华, 曾畅, 罗芳, 张贵琼, 胡小丽. 超声造影检查无创评估放射性肝损伤患者可行性研究[J]. 实用肝脏病杂志, 2020, 23(5): 674-677.
[15]	罗利红, 胡洁, 周启. LI-RADS超声分类诊断肝脏占位性病变准确性分析[J]. 实用肝脏病杂志, 2020, 23(5): 731-734.